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Background: The aim of this study was to validate the ‘Predicting Infectious ComplicatioNs in Children with Cancer’ (PICNICC)
clinical decision rule (CDR) that predicts microbiologically documented infection (MDI) in children with cancer and fever and
neutropenia (FN). We also investigated costs associated with current FN management strategies in Australia.
Methods: Demographic, episode, outcome and cost data were retrospectively collected on 650 episodes of FN. We assessed the
discrimination, calibration, sensitivity and specificity of the PICNICC CDR in our cohort compared with the derivation data set.
Results: Using the original variable coefficients, the CDR performed poorly. After recalibration the PICNICC CDR had an area
under the receiver operating characteristic (AUC-ROC) curve of 0.638 (95% CI 0.590–0.685) and calibration slope of 0.24. The
sensitivity, specificity, positive predictive value and negative predictive value of the PICNICC CDR at presentation was 78.4%,
39.8%, 28.6% and 85.7%, respectively. For bacteraemia, the sensitivity improved to 85.2% and AUC-ROC to 0.71. Application at
day 2, taking into consideration the proportion of MDI known (43%), further improved the sensitivity to 87.7%. Length of stay is the
main contributor to cost of FN treatment, with an average cost per day of AUD 2183 in the low-risk group.
Conclusions: For prediction of any MDI, the PICNICC rule did not perform as well at presentation in our cohort as compared with
the derivation study. However, for bacteraemia, the predictive ability was similar to that of the derivation study, highlighting the
importance of recalibration using local data. Performance also improved after an overnight period of observation. Implementation
of a low-risk pathway, using the PICNICC CDR after a short period of inpatient observation, is likely to be safe and has the
potential to reduce health-care expenditure.
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Fever and neutropenia (FN) is a common complication of
the treatment of childhood cancer and the leading cause of
unplanned hospital admissions (Mueller et al, 2015). A severe
infection is documented in fewer than half of all episodes (Hann
et al, 1997). Many paediatric clinical decision rules (CDRs) are
available to identify children at low risk for severe infection who
may qualify for reduced-intensity treatment (Phillips et al, 2010,
2012a). However, because of a paucity of validation and
implementation studies, most centres admit all children with FN
for intravenous antibiotics irrespective of risk status. This
approach, although safe, contributes to overtreatment, negatively
affects quality of life and increases health-care expenditure
(Haeusler et al, 2015b).
Before a CDR can be implemented it should undergo evaluation
in a population external to the derivation data set to ensure it is
safe and reproducible (McGinn et al, 2000; Phillips, 2010). Seven
paediatric FN CDRs (Rackoff et al, 1996; Klaassen et al, 2000;
Baorto et al, 2001; Santolaya et al, 2001; Alexander et al, 2002;
Ammann et al, 2003, 2010) have undergone formal validation in
centres external to the derivation studies (Madsen et al, 2002;
Dommett et al, 2009; Ammann et al, 2010; Macher et al, 2010;
Miedema et al, 2011). Of these, only two have been shown to be
reproducible, highlighting the importance of validation before
implementation (Klaassen et al, 2000; Ammann et al, 2010).
Contributing to discordant derivation and validation results are
differences in study methodology and definitions and insufficient
sample sizes (Phillips et al, 2012b). To overcome this, the
‘Predicting Infectious ComplicatioNs in Children with Cancer’
(PICNICC) collaboration completed an individual participant data
(IPD) meta-analysis of data from 22 groups and derived a new
predictive model. The PICNICC model uses the following weighted
variables to predict microbiologically documented infection (MDI):
malignancy, maximum temperature, clinically severely unwell,
haemoglobin, white cell count and absolute monocyte count
(Phillips et al, 2016). Although subjective, ‘severely unwell’ was
shown to be a highly sensitive predictor of MDI and is included in
the adult Multinational Supportive Care in Cancer low-risk scoring
system (Klastersky et al, 2000; Phillips et al, 2016).
The aim of this study was to validate the PICNICC CDR in
children with cancer presenting to the emergency department (ED)
with FN at an Australian hospital. To extend our understanding of
the CDR, originally developed for implementation at FN
presentation, we also explored the predictive performance of the
PICNICC rule at day 2. Finally, to provide a baseline under-
standing of potential impact of low-risk management strategies we
investigated costs associated with current FN management
strategies.
MATERIALS AND METHODS
Data collection. Consecutive episodes of outpatient-onset FN in
children (ageo19 years) with cancer and receiving chemotherapy
or haematopoietic stem cell transplant (HSCT) at the Royal
Children’s Hospital (RCH), Melbourne, were retrospectively
identified from electronic databases. The RCH is a tertiary
paediatric hospital with a 26-bed haematology/oncology and
HSCT unit and the majority of patients are treated on Children’s
Oncology Group chemotherapy protocols. Multiple, discrete FN
episodes per patient were allowed. Episodes were excluded if they
were receiving antibiotics for treatment of documented infections.
Inpatient-onset FN was also excluded as these events are difficult to
consistently identify retrospectively from hospital records and
because they tend to occur in very high-risk patients (including
AML or HSCT recipients) who would not be considered for early
discharge at our institution.
Demographic, episode and clinical outcome data were obtained
from scanned electronic medical records and entered into REDCap
database (Harris et al, 2009). Data were collected by a research
assistant blinded to the PICNICC CDR. In-patient costs were
obtained from the hospital activity-based costing system. This
captures direct and indirect medical costs that are collated into
resource use groups including medical, nursing, diagnostics and
pharmacy.
The six PICNICC variables were collected at two time points:
presentation (0–4 h) and day 2 (D2). For maximum temperature,
the highest temperature in the preceding 12 h or in the ED was
used. Data for D2 assessment were taken between 0900 and 1100 h
to replicate existing practice. Outcome data were collected at the
end of FN episode. The date and time bacteraemia episodes were
known were extracted from the electronic pathology database. For
all other MDI, the date and time the infection was documented in
the medical record were used. An infectious diseases physician
(GMH) reviewed microbiological results to ensure the correct
diagnosis was assigned.
There were no changes to empiric antibiotic protocols during
the study period that included piperacillin–tazobactam (all
patients) plus amikacin (if high-risk cancer protocol, inpatient-
onset FN or systemic compromise) (Haeusler et al, 2013). At RCH,
patients with acute myeloid leukaemia (AML) and immediately
post HSCT are routinely admitted during the neutropenic phase
for FN observation and therefore unlikely to present to the
emergency department with fever. A formal low-risk FN pathway
was not in clinical use during the study period and discharge was
typically considered in patients with evidence of marrow recovery,
negative blood cultures at 48 h and who have been afebrile for at
least 24 h.
Microbiological investigation of FN routinely includes two
blood culture sets and a urine for culture (all patients) as well as
nasal swab for respiratory virus PCR; chest X-ray; stool for culture,
Clostridium difficile toxin assay and viral PCR; and skin or wound
swab for culture and viral PCR (as clinically indicated and
according to local guidelines and international recommendations
(Lehrnbecher et al, 2012)).
Definitions. Fever was defined as a single tympanic temperature
of X38 1C and neutropenia as an absolute neutrophil count of
o1000/mm3. ‘Severely unwell’ was any of severe sepsis or septic
shock (defined according to Goldstein et al, 2005), altered
conscious state (Glasgow Coma Score o15 or only responsive to
voice or pain) or documented as ‘severely unwell’ or equivalent in
the patient record (Goldstein et al, 2005).
Outcomes were defined according to international consensus
recommendations (Goldstein et al, 2005; Haeusler et al, 2015a).
An MDI was defined as an infection that was clinically detectable
and microbiologically proven. Bacteraemia was defined as a
recognised pathogen (including viridans group streptococci in
the setting of mucositis or neutropenia) fromX1 blood cultures or
common commensals from X2 blood cultures drawn on separate
occasions (Haeusler et al, 2015a). Bacterial MDI was any of
bacteraemia, bacterial respiratory infection, urinary tract infection
(UTI) or skin and soft infection (SSTI).
Data analysis. Validation of the PICNICC rule consisted of two
components: statistical validation and clinical utility (Altman and
Royston, 2000).
Statistical validation comprised assessment of the discrimination
and calibration of the new data set compared with the derivation
data set (Steyerberg, 2009; Phillips et al, 2016). Calibration is
assessed by comparing how accurately the predicted risk of MDI
fits with the observed rate of MDI, and discrimination is the ability
of predicted values to categorise the episode correctly, given
different threshold values. These statistical assessments were made
by comparing the area under the receiver operating characteristic
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(AUC-ROC) curve to assess the overall discriminatory ability and
calibration slope that estimates how precisely the predicted
probability of infection meets the measured values (Steyerberg, 2009).
To establish baseline calibration variables, a separate, initial
survey of 101 episodes was performed using the same methodology
and recalibration was undertaken as described by Steyerberg
(2009). First, the mean observed outcomes in the Australian data
set (n¼ 101) were compared with those in the derivation data set.
These were similar (23.5 vs 21.5%), and simple recalibration using
this change in intercept did not markedly affect the calibration.
Second, the predictors were modified by multiplying the estimated
overall calibration slope along with the essentially unchanged
intercept. Both the intercept and variable coefficients of the
original PICNICC model were adjusted during the recalibration
process. Details of the model, including original and adjusted
variable coefficients, are available in the Supplementary
Information (Phillips et al, 2016). There was no significant
difference in type of cancer or temperature between the validation
group (n¼ 650) and the baseline calibration group (n¼ 101). The
validation group had a marginally higher mean total white cell
count (0.56 vs 0.48, difference 0.08 CI 0.07–0.9) than the
calibration group.
Clinical utility was assessed by calculating the sensitivity,
specificity, positive predictive value (PPV) and negative predictive
value (NPV) of dichotomising at p10% chance of MDI, and
comparing this with the derivation data set (Steyerberg, 2009).
Data were presented for non-recalibrated and recalibrated
PICNICC CDR for any MDI and the recalibrated CDR for
bacteraemia and bacterial MDI.
The clinical utility of the PICNICC rule at D2 was assessed in
two ways. First, as described by the Swiss Paediatric Oncology
Group (SPOG), using variables collected at presentation, the
sensitivity of the rule at D2 (between 0900 and 1100 h) was
determined by combining the information on episodes with
MDI known at that time (Proportionknown¼MDIknown/MDI total)
with the results of prediction on the remaining episodes
(Sensitivitycombined¼ Proportionknownþ Sensitivitypredicted
(1–Proportionknown)) (Ammann et al, 2010). Second, variables
collected on D2 were used to determine chance of MDI. Episodes
that had already been shown to have any of MDI, severe sepsis/
septic shock or transferred to ICU before D2 assessment were
excluded from analysis, assuming that they would be classified as
high risk.
Outcomes were presented according to underlying risk status.
Continuous data were presented as median and interquartile range.
Mann–Whitney U-test was used to estimate P-values for
continuous data and Fisher’s exact test for categorical data. For
between-patient utility of the score we undertook a hierarchical
logistic regression analysis nesting the individual episodes within
the separate patients to examine the contribution of the patient
identifier to variation in accuracy of predicting MDI. The analysis
was restricted to patients with multiple episodes, and modelled the
predictive ability of the presentation PICNICC score with the
individual as a random effect modifier, using the lme4 package in R
(R Foundation for Statistical Computing, Vienna, Austria). All
tests were two tailed, and a P-value of o0.05 was considered
statistically significant.
Cost data were presented as mean and s.d. Differences in mean
and median were compared using parametric (t-test) and the
nonparametric (Mann–Whitney U) tests.
Sample size. International data indicate that MDI occurs in
between 18 and 25% of episodes of FN (Hann et al, 1997; Phillips
et al, 2010, 2012a). For validation, 650 FN episodes, with an
estimated event rate of 18%, were required for 80% power to
show AUC-ROC of the PICNICC model is X0.660. This was
the AUC-ROC of the simplest version of the original PICNICC
CDR that included only two variables: tumour type and
temperature.
Ethics. The study was approved by the RCH Human Research
Ethics Committee and, given the retrospective nature, informed
consent was not required (35034B).
RESULTS
A total of 294 324 children presented to the RCH ED between
November 2011 and June 2015, of whom 3854 (1.3%) had a
diagnosis of cancer. From this cohort, there were 650 episodes of
FN occurring in 327 patients (median 2 episodes, range 1–7).
Demographic data are summarised in Table 1. The most
common malignancy was acute lymphoblastic leukaemia, of which
39, 72, 77, 19 and 121 FN episodes occurred in induction,
consolidation, delayed intensification, interim maintenance and
maintenance phases, respectively (4 unknown).
A pre-antibiotic blood culture was performed in all episodes,
with 448 (68.9%) having two or more. Urine was taken for culture
in 328 (50%) episodes, including 102 episodes pre-antibiotics. Of
these pre-antibiotic urine cultures, a pathogen was detected in 14
(14%). Additional microbiological investigations that were per-
formed according to clinical symptoms included viral respiratory
PCR in 185 (28%), chest X-ray in 145 (22%), stool for culture and
PCR in 100 (15%) and a skin swab in 69 (11%) FN episodes.
Of the 650 FN episodes, 244 had one or more microbiologically
or clinically documented infections (209 had 1; 31 had 2; and 4 had 3).
The primary cause of fever was attributed to an MDI in 153
(23.5%) episodes (bacteraemia in 61; other MDI in 92). Of the 202
episodes with a single pre-antibiotic blood culture, 8 (1.2%) had a
common commensal identified (4 with Micrococcus spp.; 4 with
coagulase negative staphylococci). An alternative source of
infection was identified in four, and in the remaining, ‘likely
contaminant’ was documented.
Validation at presentation. The recalibrated PICNICC rule had
an AUC-ROC of 0.638 (95% CI 0.590–0.685) and a calibration
slope of 0.24. A total of 231 episodes (35.5%) were identified as low
risk for MDI (Table 2). Of these, 33 had an MDI, including 9
episodes with bacteraemia.
The median time to diagnosis of any MDI was 23.2 h (IQR
18.1–47.5 h) in the low-risk group and 23.3 h (IQR 15.3–41.4 h)
in the high-risk group (P¼ 0.56). The median time to diagnosis
of a bacteraemia was 20.0 h (IQR 19.7–26.2 h) in the low-risk
group and 22.0 h (IQR 16.8–28.1 h) in the high-risk group
(P¼ 0.85).
Detailed comparison of the clinical utility of the PICNICC CDR
in the derivation and validation study is presented in Table 3.
Without recalibration, and using the original PICNICC coeffi-
cients, the CDR performed poorly, only classifying 3.2% of
episodes as low risk. For bacteraemia alone, the sensitivity of the
recalibrated PICNICC CDR improved from 78.4% to 85.2% and
the AUC-ROC from 0.64 to 0.71. With regard to multiple episodes
per patient, individual ID accounted for 10% of variation and was a
highly nonsignificant predictor (P¼ 0.999).
Validation at day 2. Day 2 assessment occurred a median of
19.1 h after presentation (IQR 15.1–24.0 h). Sixty-six (43%) MDI
episodes were diagnosed before D2 assessment: 11 in the low-risk
group including 3 episodes with bacteraemia (Pseudomonas
aeruginosa in 2; Escherichia coli in 1) and 55 in the high-risk
group, including 25 episodes with bacteraemia.
Taking into consideration proportion of MDI known at
reassessment, the sensitivity of the PICNICC rule applied to
presentation variables was 87.7% (Ammann et al, 2010). Pathogens
responsible for the bacteraemia episodes in low-risk group that
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were not identified before D2 included Staphylococcus epidermidis
(2 episodes), Staphylococcus aureus and Granulicatella adiacens,
Citrobacter braakii and viridans group streptococci (2 episodes).
There were four viral respiratory tract infections, four bacterial
UTI, three bacterial SSTI, three episodes of C. difficile colitis and
two of HSV gingivostomatitis in the low-risk group that were also
not identified before D2.
Day 2 variables were available for 514 FN episodes (Table 2): full
blood count was unavailable in 131 and temperature not
documented in 5. There was no significant difference in tumour
type, maximum temperature, white cell count, severity of illness
and MDI between episodes with and without missing data on D2.
After exclusion of 71 FN episodes that had been shown to have any
of MDI, severe sepsis/septic shock or ICU admission by D2
assessment, 443 episodes were available for analysis. In all, 193
episodes were identified as low risk. Of these, 28 had an MDI,
including 8 episodes with bacteraemia. There were 65 episodes
identified as low risk at presentation and D2 (Figure 1), of which 5
had an MDI (S. epidermidis bacteraemia, S. aureus SSTI, herpes
simplex virus gingivostomatitis, respiratory syncytial virus respira-
tory infection and C. difficile colitis). The remaining 23
misclassified MDI were identified as high risk at presentation.
There were 46 episodes identified as low risk at presentation and
high risk on D2, of which 9 (19.6%) had an MDI. Conversely, 128
episodes were high risk at presentation and low risk on D2 of
which 23 (17.9%) had an MDI. Finally, 204 remained high risk,
including 36 (17.6%) with a MDI.
The sensitivity of the PICNICC rule applied to clinical variables
collected on D2 was 61.6% (Table 3).
Clinical outcomes. Outcomes according to presentation risk
status are outlined in Table 4. There were four episodes of
Gram-negative bacteraemia and six with Gram-positive bacter-
aemia in the low-risk group. There were no serious medical
complications (any of late-onset severe sepsis, admission to ICU or
death within 30 days) in low-risk episodes with bacteraemia.
One episode (0.4%) in the low-risk group had late-onset severe
sepsis/septic shock (time to diagnosis 4.5 h) and was subsequently
admitted to ICU (time to admission 8.9 h). There was one further
ICU admission in the low-risk group 3.3 h after presentation. The
median hospital length of stay (LOS) was significantly lower in the
low-risk group compared with the high-risk group (3.5 days vs 6.9
days). No deaths occurred in the low-risk group.
Resource use. Admission costs according to resource use are
presented in Table 5. The total average cost assigned to low-risk
episodes was significantly less than high-risk episodes (mean
difference AUD 10 758). However, the total average cost per day of
in-patient services was not significantly different between the
groups (Table 6). Inpatient medical and nursing/allied health were
the highest resource use categories across both groups.
DISCUSSION
This is the first time the PICNICC CDR, developed from IPD
meta-analysis of existing paediatric FN CDR, has undergone
validation in a population entirely external to the derivation
studies. For prediction of any MDI, both the non-recalibrated and
the recalibrated rule performed poorly as reflected by the low
AUC-ROC and calibration slope. This is in keeping with previously
published validation studies where the sensitivity and specificity
are frequently lower than derivation study (Macher et al, 2010;
Miedema et al, 2011; Delebarre et al, 2014). However, for
bacteraemia, arguably the most serious MDI, the AUC-ROC
showed moderate discrimination and sensitivity was similar to that
of the derivation study with an even greater specificity. In fact, the
performance of the recalibrated PICNICC rule in our population in
the prediction of bacteraemia exceeded the performance of many
of the published CDR that have undergone external validation
(Macher et al, 2010; Phillips et al, 2012a). Whereas the non-
recalibrated PICNICC CDR had the greatest sensitivity, the
specificity was compromised with very few episodes being
identified as low risk.
Reassuringly, although 33 episodes identified as low risk at
presentation subsequently had an MDI, including 9 with a
bacteraemia, there were very few serious medical complications
Table 1. Demographic data for paediatric FN episodes
Median age, years (IQR) 5.9 (3.5–10.3)
Male sex, n (%) 327 (50.3)
Haematological malignancy, n (%) 412 (63.4)
ALL, n 332
Lymphoma, n 49
AML, n 11
Other haem malig., n 20
Solid tumour, n (%) 238 (36.6)
Sarcoma, n 112
Brain tumour, n 55
Neuroblastoma, n 35
Other solid tumour, n 36
Relapse/refractory disease, n (%) 52 (8)
Leukaemia/lymphoma, n 29
Solid tumour, n 23
Prior HSCT
Allogeneic, n (%) 8 (1.2)
Autologous, n (%) 15 (2.3)
Central venous access device in situ, n (%) 620 (95)
Implanted port, n 435
Tunnelled external catheter, n 172
PICC, n 13
PJP prophylaxis, n (%) 516 (79.4)
Co-trimoxazole, n 508
Other, n 6
Fungal prophylaxis, n (%) 88 (13.5)
Yeast-active (fluconazole), n 64
Mould-active (itra/vori/posaconazole), n 24
Viral prophylaxis, n (%) 41 (6.3)
HSV/VZV (acyclovir), n 41
Antibacterial prophylaxis, n (%) 0
b-Lactam allergy, n (%) 32 (4.9)
Non life-threatening, n 25
Life-threatening, n 2
Unknown type, n 5
Abbreviations: ALL¼ acute lymphoblastic leukaemia; AML¼ acute myeloid leukaemia;
FN¼ fever and neutropenia; haem malig.¼haematological malignancy; HSCT¼
haematopoietic stem cell transplant; HSV¼ herpes simplex virus; IQR¼ interquartile range;
PICC¼peripherally inserted central catheter; PJP¼Pneumocystis jirovecii pneumonia;
VZV¼ varicella zoster virus.
Table 2. The PICNICC rule predicted risk status vs
microbiologically documented infection diagnosis
MDI, n (%) No MDI, n (%) Total
Presentation
High risk (X10% chance MDI) 120a (18.4) 299 (46) 419
Low risk (o10% chance of MDI) 33b (5.1) 198 (30.5) 231
Day 2 (data available for 443 episodes)
High risk (X10% chance MDI) 45 (10.2) 205 (46.3) 250
Low risk (o10% chance of MDI) 28 (6.3) 165 (37.2) 193
Abbreviations: MDI¼microbiologically documented infection; PICNICC¼Predicting Infec-
tious ComplicatioNs in Children with Cancer.
a
A total of 55 (45.8%) fever and neutropenia (FN) episodes had MDI diagnosed before day 2
review.
b
A total of 11 (33.3%) patients had MDI diagnosed before day 2 review.
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in this group. There were no infection relapses or deaths and only
two episodes required ICU admission, both of which occurred
within the first 9 h of presentation. Although the impact of hospital
admission and IV antibiotics in the prevention of these serious
outcomes remains unknown, this low rate is in keeping with
studies of oral and outpatient antibiotic management of FN
(Morgan et al, 2016). At D2, 11 (33.3%) of the MDI in the low-risk
group were known including the three serious Gram-negative
bacteraemia episodes. Of the remaining unknown MDI, at least six
did not require broad-spectrum IV antibiotics. This suggests that
some missed MDI may be of less clinical significance and therefore
less likely to result in readmission as compared with bacteraemia.
Application of the rule at D2 using variables collected at
presentation (therefore unaffected by hospital admission and
antibiotics) and taking into consideration the proportion of
episodes with an MDI known at reassessment, the sensitivity of
the PICNICC rule improved to 88%, lying within the 95%
confidence interval of the derivation study (Phillips et al, 2016).
This improvement is in keeping with results of the SPOG rule
predicting adverse outcome in children with FN that also
performed better at D2 (Ammann et al, 2010). Conversely, the
sensitivity of the rule applied to clinical variables collected at D2
dropped to just 61.6%, despite the exclusion of episodes where
MDI was already known. The impact of admission, observation
and treatment with broad-spectrum antibiotics on the patients
clinical status may in part, explain this marked reduction in
sensitivity. These data suggest methodology used by SPOG yield
more sensitive, and hence clinically meaningful, results as
compared with using variables collected after a period of inpatient
treatment.
Variability in results obtained in derivation and validation of
clinical decision rules is well recognised and underpins the
rationale for vigorous testing in a population external to the
original derivation set (Phillips, 2010). Factors contributing to this
variability include the unavoidable differences in time and
geography as well as differences in the type of chemotherapy
treatment protocols used, all of which are relevant to our results.
The PICNICC CDR was developed from a global collaboration of
15 countries, none of which included Australia, and from studies
that were published in the decades before this validation study
(Phillips et al, 2016). The impact of geography is most evident in
the results of the PINDA rule where validation data support its use
in Chile but not Europe and highlights the importance of local
validation before implementation irrespective of results obtained at
other centres (Santolaya et al, 2001; Phillips et al, 2012a).
Furthermore, although the influence of region-specific chemother-
apy protocols, which adapt and change over time, has not been
formally explored, it is likely to also contribute to discordant
derivation and validation results. Rule recalibration, a unique
feature of our study, is one way the impact of these inevitable
differences can be reduced.
Little is known about the costs of treating FN in children in
Australia. International data support the potential cost savings of
oral or intravenous outpatient therapy for low-risk FN, with
reductions in hospital bed-days accounting for the highest savings
(Wiernikowski et al, 1991; Santolaya et al, 2004; Teuffel et al,
2011). Our data similarly show that LOS is the main contributor to
overall cost. Accordingly, total cost is higher in the high-risk group
because of longer LOS, with no difference in cost per day between
the groups. In the absence of a low-risk pathway at our centre,
these patients remain in hospital for a median of 3.5 days. With
increasing evidence that discharge, as early as 24 h, is safe and
feasible, these data also provide an estimate of the potential for
reductions in in-patient hospital expenditure of up to AUD 2183
per day following implementation of a formal low-risk pathway
(Morgan et al, 2016).
Although retrospective, this is the one of the largest external
paediatric FN validation studies conducted to date and had a
sufficient sample size to compare derivation and validation results.
To avoid recruitment bias, we collected all consecutive episodes of
outpatient-onset, chemotherapy-induced FN. However, because
inpatient-onset FN was excluded, very few patients with AML or
immediately post-HSCT were included. Although traditionally
considered high risk for MDI, it is unclear from our study how the
PICNICC rule applies to these patients. Another potential
limitation was in the allocation of MDI to FN episodes. Although
this would not have affected bacteraemia, it may have resulted in
incorrect allocation of viral respiratory infections based on highly
sensitive PCR testing. Reassuringly, this error would have under-
played the true performance of the PICNICC rule in our
population. It is also possible that the date and time that non-
Table 3. Comparison of the discrimination and clinical utility of the PICNICC rule in the original derivation study and the external
validation study (with 95% confidence intervals)
Outcome AUC-ROC Low-risk, n (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Original PICNICC CDR (derivation study results) (Phillips et al, 2016)
MDI 0.72 (0.71–0.76) 163 (18.1) 91.5 (87.3–94.4), 21.2 (18.3–24.5) 29 (25.8–32.2) 87.7 (81.8–91.9)
Non-recalibrated PICNICC CDR (presentation validation results)
MDI 0.64 (0.59–0.69) 21 (3.2) 98.7 (95.4–99.8) 3.8 (2.5–6.0) 24 (20.8–27.5) 90.5 (71.1–98.3)
Recalibrated PICNICC CDR (presentation validation results)
MDI 0.64 (0.59–0.69) 231 (35.5) 78.4 (71.3–84.2) 39.8 (35.6–44.2) 28.6 (24.5–33.1) 85.7 (80.6–89.6)
Bacteraemia 0.71 (0.64–0.77) 231 (35.5) 85.2 (74.3–92.0) 37.8 (34–41.8) 12.4 (9.6–15.9) 96.1 (92.8–97.9)
Bacterial MDIa 0.67 (0.61–0.73) 231 (35.5) 80.5 (70.6–87.6) 37.9 (34.0–41.9) 15.8 (12.6–19.5) 93.1 (89.0–95.7)
PICNICC CDR (day 2 validation results)
MDI (n¼ 443) ND 193 (43.6) 61.6 (50.2–71.9) 44.6 (39.6–49.7) 18.0 (13.7–23.2) 85.5 (79.8–89.8)
Abbreviations: AUC-ROC¼ area under the receiver operating characteristic curve; CDR¼ clinical decision rule; MDI¼microbiologically documented infection; ND¼not done; NPV¼ negative
predictive value; PICNICC¼Predicting Infectious ComplicatioNs in Children with Cancer; PPV¼positive predictive value.
a
Bacterial MDI includes any of bacteraemia, urinary tract infection, skin and soft tissue infection.
Risk classification using
presentation variables  
Risk classification using
day 2 variables 
FN episodes with day 2
variables 443
193 
Low risk
65 
Low risk
128
High risk
250 
High risk
46 
Low risk
204 
High risk
Figure 1. Risk classification of FN episodes using variables collected
on day 2 (risk classification using presentation variables available for
comparison).
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bacteraemia MDIs were known were earlier than what was
documented in the medical records. This would have under-
estimated the sensitivity of the PICNICC rule using the SPOG
methodology that takes into account the number of MDI known at
time of assessment. Finally, although all episodes had a blood
culture as part of the diagnostic work up for MDI, only 50% had a
Table 4. Detailed outcome data according to risk status on presentation
Low risk (n¼231) High risk (n¼419) P-value
Primary diagnosis, n (%) o0.001
MDI (bacteraemia) 9 (3.9) 52 (12.4)
MDI (other) 24 (10.4) 68 (16.2)
CDI 34 (14.7) 57 (13.6)
Fever without focus 164 (71.0) 242 (57.8)
Gram-negative bacteraemia, n 4a 30a ND
Escherichia coli 1 13
Klebsiella spp.  7
Pseudomonas aeruginosa 2 3
Enterobacter cloacae  2
Acinetobacter baumanii  2
Capnocytophaga spp.  2
Citrobacter braakii 1 
Fusobacterium spp.  1
Gram-positive bacteraemia, n 6a 30a ND
Viridans group streptococci 2 15
Staphylococcus aureus 1 4
Coagulase negative staph 2 4
Kocuria kristinae  2
Granulicatella adiacens 1 
Enterococcus faecalis  1
Group B streptococcus  1
Clostridium spp.  1
Rothia spp.  1
Streptococcus pneumoniae  1
Other MDI, n ND
Viral URTI 6 33
Viral LRTI 4 7
Bacterial urinary tract infection 4b 11c
Bacterial SSTI 3d 3e
C. difficile colitis 4 4
Gastroenteritis  4f
HSV gingivostomatitis 3 4
Candida oesophagitis  1
Herpes zoster  1
Clinically documented infection, n ND
URTI 15 27
LRTI 7 14
SSTI 8 6
Sinusitis 1 0
Enterocolitis 0 6
Tooth abscess 0 2
Other 3 2
Sepsis at ED presentation, n (%) o0.001
No sepsis 44 (19.0) 25 (6.0)
Sepsis 184 (79.7) 379 (90.5)
Severe sepsis/septic shock 3 (1.3) 15 (3.5)
Late onset (44 h) severe sepsis, n (%) (time to dx) 1 (0.4) (4.5 h) 2 (0.5) (259 h, 246 h) 40.99
Admission to ICU, n (%) 2 (0.9) 15 (3.6) 0.04
Median time to ICU, h (IQR) 6.1 (3.3–8.9) 13.5 (6.3–291.9) 0.37
Median ICU LOS, h (IQR) 32.6 (30.0–35.3 h) 20.0 (11.3–64.5 h) 0.52
Median hospital LOS, days (IQR) 3.5 (2.5–5.7) 6.9 (3.9–11.8) o0.001
Relapse of primary MDI within 30 days 0 3 (2.5)g 40.99
30-Day all-cause mortality, n (%) 0 2 (0.5) 0.54
Abbreviations: CDI¼ clinically defined infection; dx= diagnosis; ED¼emergency department; HSV¼ herpes simplex virus; ICU¼ intensive care unit; IQR¼ interquartile range; LOS¼ length of
stay; LRTI¼ lower respiratory tract infection; MDI¼microbiologically defined infection; ND¼ not done; SSTI¼ skin and soft tissue infection; URTI¼ upper respiratory tract infection.
a
Polymicrobial bacteraemia in 1 low-risk episode (1 had 2 pathogens) and 7 high-risk episodes (6 had 2 pathogens, and 1 had 3 pathogens).
b
Pathogens include E. coli, K. pneumoniae, P. mirabilis and Group B streptococcus.
c
Pathogens included E. coli (3 ), C. koseri, E. cloacae and Group B streptococcus.
d
Pathogens included methicillin-sensitive S. aureus (MSSA) ( 2) and P. aeruginosa.
e
Pathogens included MSSA, methicillin-resistant S. aureus (MRSA) and P. aeruginosa.
f
Pathogens included norovirus, Cryptosporidium spp., Salmonella enterica serova Mbandaka and Campylobacter jejuni.
g
Included three episodes of bacteraemia: E. coli, E. cloacae and P. aeruginosa.
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urine culture. The clinical impact of this is likely to be low as no
patient, including those without a sample taken, had a relapsed
UTI within 30 days of the FN episode.
This comprehensive validation of the internationally derived
PICNICC CDR highlights the importance of CDR recalibration
using local data, and provides a simple framework to achieve this.
Although the recalibrated PICNICC rule did not perform as well in
our cohort as compared with the derivation study for prediction of
any MDI, the performance is promising for bacterial MDI and
after an overnight period of observation. Our study also provides a
contemporary and detailed understanding of the variety of causes
of FN, the potential limitations of the PICNICC CDR and
reassurance as to the low rate of serious medical complications.
Implementation of a low-risk pathway, using the recalibrated and
validated PICNICC CDR after an overnight period of inpatient
observation and in context of a structured low-risk outpatient
program with careful follow-up, is likely to be safe and has
the potential to reduce health-care expenditure. Centres plan-
ning low-risk FN management strategies should consider
using the PICNICC rule after local validation and recalibration.
Following implementation, further research is required to assess
the clinical, psychosocial and economic impact of this model
of care.
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